To appraise the clinical and cost effectiveness of lenvatinib within its marketing authorisation for advanced, unresectable, untreated hepatocellular carcinoma.
 
Status In progress
Process STA pre-2018
ID number 1089

Provisional Schedule

Expected publication 19 December 2018

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Eisai (lenvatinib)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Hepatitis C Trust
Professional groups Association of Cancer Physicians
  British Association of the Study of the Liver
  British Society of Gastroenterology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Bayer (sorafenib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Foundation for Liver Research
  Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
08 November 2018 - 22 November 2018 Final appraisal determination
27 September 2018 Committee meeting: 2
08 August 2018 - 30 August 2018 Appraisal consultation: 1
30 May 2018 Committee meeting: 1
07 December 2017 Invitation to participate
23 August 2017 - 21 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance